Tesamorelin (TH9507): Molecular Characterization and Receptor Pharmacology — A Research Reference

Tesamorelin is a 44-amino-acid synthetic analogue of growth hormone-releasing hormone (GHRH), a hypothalamic peptide of the secretin superfamily that is itself 44 residues in length [4]. The full-length native sequence and the analogue are identical in primary structure; they differ by a single covalent modification at the amino terminus.

That modification is a trans-3-hexenoyl group, a six-carbon unsaturated acyl chain, attached to the N-terminal residue. Amide-bond formation between the acid and the free α-amino group adds a defined increment of approximately 96 daltons to the mass of the unmodified peptide — a figure that makes the modification directly verifiable by mass measurement rather than inferable from the label.

The rationale for placing the modification at that specific position is enzymatic. Native GHRH is cleaved rapidly in plasma by dipeptidyl peptidase-4, which acts at the amino terminus and releases an N-terminally truncated product; the cleavage site and the kinetics of that degradation were characterized in vitro and the truncated product identified as pharmacologically inactive at the receptor [2]. Blocking the α-amino group with an acyl substituent sterically obstructs the protease's approach while leaving the receptor-engaging region of the sequence chemically unaltered. This is a general strategy in peptide engineering — modify the site of proteolytic attack, preserve the site of receptor recognition — and tesamorelin is among its clearer illustrations.

Because the sequence responsible for receptor engagement is unmodified, the analogue's characterized engagement profile at the GHRH receptor closely parallels that of the native peptide. The modification addresses stability, not binding.

The Target Receptor

The GHRH receptor (GHRHR) is a class B G-protein-coupled receptor of the secretin family, first cloned and functionally expressed from pituitary tissue in 1992 [3]. Like other class B receptors it couples principally to Gαs, and receptor activation stimulates adenylyl cyclase with a corresponding rise in intracellular cyclic AMP.

Class B GPCRs share an architecture distinct from the more numerous class A receptors: a large extracellular domain that captures the C-terminal portion of the peptide ligand, and a transmembrane bundle engaged by the peptide's N-terminal residues [5]. This two-domain binding model explains why N-terminal modifications in this receptor family are pharmacologically consequential in a way that C-terminal ones often are not — the amino terminus is the activation-determining region.

A cryo-electron microscopy structure of the activated GHRHR in complex with its G protein has resolved the receptor's ligand-bound conformation, defining the peptide-binding groove and the conformational transitions accompanying activation [1]. Comparable structures for related class B receptors, including the glucagon receptor, provide the structural context in which GHRHR is now interpreted [6].

For receptor-pharmacology work, tesamorelin is therefore a defined tool: a full-length GHRH sequence with a single characterized N-terminal acyl modification, engaging a structurally resolved class B GPCR through a well-described two-domain mechanism.

A 44-residue synthetic peptide presents a more demanding characterization problem than a short sequence, simply because there are more coupling steps at which synthesis can fail.

Mass spectrometry confirms the intact molecular mass. For this analogue the measurement carries a second piece of information: because the trans-3-hexenoyl group contributes a defined increment, an observed mass corresponding to the unmodified 44-residue chain rather than the acylated one identifies a materially different compound.

Reversed-phase HPLC resolves the main peak from related substances and yields the purity figure. In long synthetic peptides the predominant related substances are deletion sequences, in which a single residue failed to couple. These differ from the target by one amino acid and can be chromatographically close to it, which is why the trace itself is more informative than the headline percentage.

Amino acid analysis is reported on some certificates as an orthogonal confirmation of composition. It hydrolyses the peptide and quantifies the constituent residues, providing a compositional check independent of the mass measurement.

Net peptide content accounts for counter-ions and residual water and determines how much peptide a nominal milligram figure represents — relevant because peptides of this class are typically isolated as acetate salts.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify; solutions of GHRH-family peptides are treated as short-lived relative to the lyophilized form, and repeated freeze–thaw cycling is avoided.

The N-terminal acyl modification improves resistance to enzymatic cleavage in biological media but confers no advantage against the physical degradation routes that govern storage — aggregation, oxidation, and adsorption to container surfaces. At 44 residues the chain is long by synthetic-peptide standards and presents correspondingly more surface for aggregation under mechanical stress, so agitation is minimised as a matter of routine.

Material supplied by HEEZ Research is research-grade and is not a pharmaceutical product. No manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade tesamorelin is accompanied by an independent certificate of analysis specific to that lot.

Tesamorelin is the full 44-residue GHRH sequence bearing a single trans-3-hexenoyl modification at its amino terminus, a substitution placed to obstruct dipeptidyl peptidase-4 cleavage while preserving the receptor-engaging region. It is characterized against GHRHR, a class B secretin-family GPCR coupling to Gαs, whose activated conformation has been resolved structurally. Analytical verification rests on mass confirmation of the acyl modification, chromatographic resolution of deletion sequences, and batch-specific reporting of net peptide content.